Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Oral Oncology

Volumn 81, Issue , 2018, Pages 45-51

  Ferris, Robert L ^a   Blumenschein, George ^b   Fayette, Jerome ^c   Guigay, Joel ^d   Colevas, A Dimitrios ^e   Licitra, Lisa ^f   Harrington, Kevin J ^g   Kasper, Stefan ^h   Vokes, Everett E ⁱ   Even, Caroline ^j   Worden, Francis ^k   Saba, Nabil F ^l   Docampo, Lara Carmen Iglesias ^m   Haddad, Robert ⁿ   Rordorf, Tamara ^o   Kiyota, Naomi ^p   Tahara, Makoto ^q   Lynch, Mark ^r   Jayaprakash, Vijayvel ^r   Li, Li ^r   Gillison, Maura L ^b   more..

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e STANFORD UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY OF MICHIGAN   (United States)

^l EMORY UNIVERSITY   (United States)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ DANA FARBER HARVARD CANCER CENTER   (United States)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^p KOBE UNIVERSITY HOSPITAL   (Japan)

^q NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^r BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Carcinoma, squamous cell of head and neck; CD274 protein, human (PD L1 Protein, Human); Clinical Trial, Phase III; Head and Neck Neoplasms; Immunotherapy; Nivolumab; Papillomaviridae (HPV, Human Papillomavirus Viruses); Programmed Cell Death 1 Receptor; Survival Analysis; Survivors (Long term Survivors)

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CETUXIMAB; DOCETAXEL; METHOTREXATE; NIVOLUMAB; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; TRIACYLGLYCEROL LIPASE; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BODY WEIGHT LOSS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENERAL CONDITION DETERIORATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART FAILURE; HUMAN; HYPERAMYLASEMIA; HYPERCALCEMIA; HYPERSENSITIVITY; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY DISEASE; LIVER DISEASE; LONG TERM SURVIVAL; LUNG INFECTION; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEPHRITIS; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA; SKIN DISEASE; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WART VIRUS; DRUG THERAPY; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NIVOLUMAB; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK; SURVIVAL ANALYSIS;

EID: 85045465431     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2018.04.008     Document Type: Article

References (15)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–86.
2. Wissinger, E., Griebsch, I., Lungershausen, J., Foster, T., Pashos, C.L., The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics 32 (2014), 865–882.
3. Vigneswaran, N., Williams, M.D., Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 26 (2014), 123–141.
4. Bernier, J., Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol 5 (2008), 705–713.
5. Saloura, V., Cohen, E.E., Licitra, L., Billan, S., Dinis, J., Lisby, S., et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 73 (2014), 1227–1239.
6. Pai, S.I., Zandberg, D.P., Strome, S.E., The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 61 (2016), 152–158.
7. European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy [press release]. April 28, 2017. https://news.bms.com/press-release/bmy/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-squamous-cell- [Accessed April 13, 2018].
8. Ferris, R.L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
9. Harrington, K.J., Ferris, R.L., Blumenschein, G. Jr., Colevas, A.D., Fayette, J., Licitra, L., et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18 (2017), 1104–1115.
10. Gillison, M.L., Blumenschein, G.R., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck(SCCHN; CheckMate 141): outcomes in first-line (1L) R/M patients and updated safety and efficacy [abstract]. J Clin Oncol, 35(Suppl 15), 2017, 6019.
11. Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck(SCCHN) in the phase 3 CheckMate 141 study: a biomarker analysis and updated clinical outcomes [abstract]. Ann Oncol, 28(Suppl 5), 2017, 1043O.
12. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
13. Gillison ML, Harrington K, Ferris RL, Guigay J, Blumenschein Jr G, Fayette J, et al. Nivolumab versus investigator's choice therapy among patients with human papillomavirus (HPV)-associated squamous cell carcinoma of the head and neck (SCCHN): updated results from CheckMate 141. Poster presented at: American Head & Neck Society Annual Meeting; April 26–27, 2017; San Diego, CA.
14. OPDIVO® (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2018.
15. Bristol-Myers Squibb receives positive CHMP Opinion recommending approval of Opdivo four-week dosing schedule for advanced melanoma and previously treated renal cell carcinoma [press release]. March 26, 2018. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-positive-chmp-opinion-recommen-0 [Accessed April 4, 2018].